|
|
Article: Sirion Therapeutics Initiates Enrollment of Phase II Clinical Trial for the Treatment of Geographic Atrophy.
- Article from:
- PR Newswire
- Article date:
- December 4, 2006
CopyrightCOPYRIGHT 2006 PR Newswire Association LLC. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
TAMPA, Fla., Dec. 4 /PRNewswire/ -- Sirion Therapeutics, Inc., an ophthalmic-focused biopharmaceuticals company, announced today that it has begun enrollment of a phase II clinical trial, which will evaluate fenretinide in the treatment of Geographic Atrophy (GA) in patients with age-related macular degeneration.
The newly initiated phase II trial is a proof of concept trial being performed as a multicenter, randomized, double-masked, placebo controlled, dose-comparison trial in up to 225 patients at approximately 20 sites in the United States. The fenretinide compound was acquired by Sirion in July of this year through an acquisition of Sytera, Inc., a San ...